Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fingleton, B.
Right arrow Articles by McIntyre, J. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fingleton, B.
Right arrow Articles by McIntyre, J. O.
Clinical Cancer Research Vol. 10, 7865-7874, December 1, 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Proteinase Activity in Human and Murine Saliva as a Biomarker for Proteinase Inhibitor Efficacy

Barbara Fingleton1, Ramkumar Menon2, Kathy J. Carter1, P. Dawn Overstreet3, David L. Hachey3, Lynn M. Matrisian1 and J. Oliver McIntyre1

1 Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, Tennessee; 2 Maternal Fetal Group and Perinatal Research Center, Women’s Hospital at Centennial Medical Center, Nashville, Tennessee; and 3 Mass Spectrometry Core Laboratory, Vanderbilt Ingram Cancer Center, Nashville, Tennessee

As molecularly targeted agents reach the clinic, there is a need for assays to detect their presence and effectiveness against target molecules in vivo. Proteinase inhibitors are one example of a class of therapeutic agent for which satisfactory methods of identifying successful target modulation in vivo are lacking. This is of particular importance while these drugs are in clinical trials because standard maximum-tolerated dose-finding studies often are not suitable due to lack of toxicity. Saliva represents a readily accessible bodily fluid that can be repeatedly sampled and used for assaying in vivo effects of systemic drugs. Here we show the development of a simple assay that can be used to measure proteinase activity in saliva and proteinase inhibition after systemic treatment with three different proteinase inhibitors. A variety of gelatinolytic activities present in human and murine saliva have been assayed with a fluorescent dye-labeled substrate and assigned to different proteinase categories by inclusion of specific classes of inhibitors. Treatment of mice with either matrix metalloproteinase inhibitors or a urokinase inhibitor for a period as short as 48 hours results in levels of the drugs that can be detected in saliva by mass spectrometry and concomitant decreases in salivary proteinase activity, thus demonstrating that these inhibitors successfully modulate their targets in vivo.




This article has been cited by other articles:


Home page
Mol. Cell. ProteomicsHome page
T. Liu, W.-J. Qian, M. A. Gritsenko, W. Xiao, L. L. Moldawer, A. Kaushal, M. E. Monroe, S. M. Varnum, R. J. Moore, S. O. Purvine, et al.
High Dynamic Range Characterization of the Trauma Patient Plasma Proteome
Mol. Cell. Proteomics, October 1, 2006; 5(10): 1899 - 1913.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2004 by the American Association for Cancer Research.